TY - JOUR
T1 - Immunological configuration of ovarian carcinoma
T2 - Features and impact on disease outcome
AU - Fucikova, Jitka
AU - Coosemans, An
AU - Orsulic, Sandra
AU - Cibula, David
AU - Vergote, Ignace
AU - Galluzzi, Lorenzo
AU - Spisek, Radek
N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/10/13
Y1 - 2021/10/13
N2 - Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.
AB - Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.
KW - Carcinoma, Ovarian Epithelial/immunology
KW - Female
KW - Humans
KW - Immunosuppression Therapy/methods
KW - Immunotherapy/methods
KW - Treatment Outcome
KW - Tumor Microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85117488650&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-002873
DO - 10.1136/jitc-2021-002873
M3 - Review article
C2 - 34645669
AN - SCOPUS:85117488650
SN - 2051-1426
VL - 9
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 10
M1 - e002873
ER -